Volume 1 FAQ

85 Total Items

Question Volume 1

I don’t understand the scoring for the VCS test. Some patients passed and missed more total than others who failed. Do only rows D and E count in the scoring? When you say to follow the VCS results to monitor improvement, what do you follow? The number to D/ E that are missed or the total missed?

Answer

I think there are sections on the videos on VCS. Only rows C and D count for scoring pass or fail. You must see beyond 6 in each eye on C and beyond 5 on D. We look for improvement beginning in the high frequencies (E) marching on to D and C.

Question Volume 1

Do you generally expect to see improvements in the VCS with CSM or Welchol even if there's still a mold exposure? Also, is a one row improvement in rows C or D significant or do you want to see at least a 2 row improvement?

Answer

The first element of treatment is removal from exposure. While some patients improve with cholestyramine and Welchol, despite exposure, the rate of improvement is markedly reduced. In terms of VCS testing, a rise of one block in one column is not significant but a rise of one block from each of five columns is significant. A rise of two blocks (or a fall in two blocks) for any one column is significant.

Question Volume 1

I have a number of patients with abnormal C4a, TGF, VEGF, MMP 9, etc but a normal VCS. If I have a patient who can see rows 8 in both columns C & D prior to treatment, how do I know how long to give CSM?

Answer

VCS will show typical deficit in 92% of patients. If the patient is a case with normal VCS, you can still see interval improvement in VCS although going from 8 to 9 is a stretch. Follow labs and symptoms re the clinical time to stop CSM or switch to Welchol. If you are suggesting stopping meds, then verify ERMI or HERTSMI-2 in the home is safe.

Question Volume 1

I have 3 patients with HLA 17-2-52B that seem to have biotoxin illness. Is this considered the same as 17-2-52A? Also, can I assume in a post Lyme patient who has biotoxin illness and is homozygous for just the post-Lyme genotype (15-6-51) that mold is not part of the problem? Is the genotype that specific? Or do we still have to check the ERMI, etc.?

Answer

Yes, HLA 17-2-52B and 52A are equivalent. No one can not assume that absence of the mold susceptible genotype rules out mold illness. As MSH falls, the role of mold as a sequential problem of post Lyme patients must be always considered. ERMI testing remains mandatory. We have looked at the per cent of non-HLA susceptible patients with confirmed mold illness. It runs about 5%.

Question Volume 1

Would the basic screening labs for adults be the list of labs mentioned on your webpage:   "Secrets of Survival"?

Answer

Yes, HLA typing, C4a (Not LabCorp), TGF beta-1, MSH (Not Quest), VIP (Not LabCorp), MMP-9, Leptin, ADH/Osmolality, ACTH/Cortisol, ACLA IgG/IgA/IgM, AGA IgA/IgG, VEGF, von Willebrand’s profile (not LabCorp). Be sure to include the CD4+CD25++CD127 lo/- assay as well. In a few days we hope to hear good news from the Institutional Review Board regarding our genomics testing (after 5 years of development!), so it is possible that we will be bringing the genomics testing to clinical use. If so, then a PAXgene tube will be added as well. Stay tuned on this one.